HEDOSOPHIA
19.5.2023 09:01:27 CEST | Business Wire | Press release
Hedosophia European Growth (the "Company") today published its annual report for the period from 1 January 2022 through 31 December 2022, including audited financial statements (the "Annual Report").
The Annual Report can be downloaded from the "Documents" section on the Company's website, accessible via the following link: https://www.hedosophiaeuropeangrowth.eu/hega-documents-confirmed/.
Update to Indicative Timetable
Further to the Company’s press release dated 3 May 2023, payment of redemption proceeds will be made to holders of Units and Ordinary Shares on 24 May 2023 (instead of 23 May 2023 as was initially communicated).
About Hedosophia European Growth
The Company is a special purpose acquisition company that aimed to identify a unique investment opportunity within industries that were technology-enabled and benefited from strong underlying macro trends. The Company is sponsored by Hedosophia Group Limited, a global investor in leading technology companies.
The Company is registered with the Registrar of Companies under incorporation number 370531 and has its registered office in Grand Cayman, Cayman Islands.
More information about the Company, including the Company's initial public offering prospectus dated 12 May 2021, which was approved by the Dutch Authority for the Financial Markets (Stichting Autoriteit Financiële Markten), can be found on the Company's website: https://www.hedosophiaeuropeangrowth.eu.
Disclaimer
This announcement contains information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of Regulation (EU) No 596/2014 on market abuse.
This announcement and the Annual Report may include forward-looking statements, which are based on the Company's current expectations and projections regarding a Business Combination or liquidation, the business, the economy and other future conditions of the Company and speak only as of the date hereof. These forward-looking statements may be identified by the use of forward-looking terminology, including the terms ''believes'', "aims", "forecasts", "continues", ''estimates'', ''plans'', ''projects'', ''anticipates'', ''expects'', ''intends'', ''may'', ''will'' or ''should'' or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements reflect the Company's current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Company's business, results of operations, financial position, liquidity, prospects, growth or strategies. Forward-looking statements speak only as at the date at which they are made and the Company undertakes no obligation to update these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005098/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 16:37:00 CEST | Press release
Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standardsFDA grants Compass NDA rolling submission and review request, based on Phase 3 dataCNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD)CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be en
Banma Intelligence and Alipay Launch AI Cockpit Solution Powered by Alipay AI Pay, Enabling Seamless and Secure In-Car Transactions by Voice24.4.2026 16:04:00 CEST | Press release
At the 2026 Beijing International Automotive Exhibition (“Auto China 2026”), OS and AI technology company Banma Intelligence and Alipay today launched a new AI cockpit solution integrating Alipay AI Pay, enabling drivers to complete purchases by voice command directly from their vehicle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424618328/en/ Industry-first AI Cockpit Solution with Alipay AI Pay Unveiled “In the past two years, smart cockpits have achieved rapid advances in perception and decision-making,” said Ming Cai, Banma Intelligence Chief Product Officer. “With large models onboard, vehicles can understand user intent and make recommendations. By integrating Alipay AI Pay into our AI cockpit solution, we are removing the last friction point in the in-car smart cockpit experience - drivers simply speak to pay, no phone required.” The new AI cockpit solution initially covers two high-frequency use cases: enterta
Spatial Announces the Release 2026 1.0.1: New Enhancements Across 3D InterOp, Data Prep, Meshing, and 3D Modeling SDKs24.4.2026 15:21:00 CEST | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced new enhancements across several of its product lines. These updates further strengthen Spatial’s commitment to delivering high-performance solutions that optimize interoperability, data preparation, and advanced modeling workflows. Designed to improve efficiency and robustness across CAD translation, modeling, meshing, and simulation processes, the latest updates introduce expanded format support, enhanced PMI handling, and new capabilities for complex geometry processing. 3D InterOp NX Reader Enhancement for 2D Drawings The NX reader imports 2D drawings as visualization data from NX 2412 and later versions. glTF Writer Supports Draco Compression glTF export incorporates Draco compression for meshes and point-clouds to significantly reduce output file sizes. Enhanced Support for Reading Product Manufacturing Information
Meta Signs Agreement With AWS to Power Agentic AI on AWS Graviton Chips24.4.2026 14:10:00 CEST | Press release
The deal helps power the agentic workloads behind Meta’s AI effortsKey takeaways The deployment starts with tens of millions of Graviton cores, with the potential to expand. Meta is now one of the largest Graviton customers in the world. The deal builds on Meta's long-standing AWS relationship and use of Amazon Bedrock at scale to support its next generation of AI. Meta has signed an agreement to deploy AWS Graviton processors at scale. The deal marks a significant expansion of a long-standing partnership between the two companies as Meta builds its next generation of AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424641117/en/ The deployment starts with tens of millions of Graviton cores, with the flexibility to expand as Meta's AI capabilities grow. The deal reflects a shift in how AI infrastructure gets built: while GPUs remain essential for training large models, the rise of agentic AI is creating massive demand f
SLB Announces First-Quarter 2026 Results24.4.2026 12:50:00 CEST | Press release
Revenue of $8.72 billion increased 3% year on year GAAP EPS of $0.50 decreased 14% year on year EPS, excluding charges and credits, of $0.52 decreased 28% year on year Net income attributable to SLB of $752 million decreased 6% year on year Adjusted EBITDA of $1.77 billion decreased 12% year on year Cash flow from operations was $487 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the first-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422463846/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChange Mar. 31, 2026 Dec. 31, 2025 Mar. 31, 2025 Sequential Year-on-year Revenue $8,721 $9,745 $8,490 -11% 3% Income before taxes - GAAP basis $956 $943 $1,063 1% -10% Income before taxes margin - GAAP basis 11.0% 9.7% 12.5% 129 bps -156 bps Net income attributa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom